Invenia Group specializes in talent and executive search for the biopharma, medtech, life sciences tools, diagnostics, and healthtech sectors, focusing on sourcing commercial, technical, and operations talent across various management levels.

Invenia Group

Invenia Group | 75,073 followers on LinkedIn. Global Talent &amp; Executive Search Specialists to the Pharma, Scientific Process &amp; Technology, and Medical Device markets | We are Invenia, a global search and talent firm specialising in the pharmaceutical, scientific and process technology and medical device and technology sectors.

Established in 2009, with a commitment to support our clients to build successful businesses, we have grown into a leading supplier across major global markets. We work with trail-blazing start-ups, SMEs and global leaders sourcing the very best in commercial, technical, strategic and executive talent.

I build executive board teams in dynamic and emerging markets, specializing in Technology, Digital Infrastructure, and Supply Chain.

Chris Pickles

I help pharmaceutical companies connect with senior professionals across Europe and the US.

Christine Sands

Director @ Invenia Group - Global Life Science, Diagnostics & Chemistry - Talent and Executive Search Specialist

Andrew Maddison

🧬I help connect commercial professionals within the life sciences & diagnostics industry with biotechnology companies across Europe🧬

Revna Cömertpay

#ANDYSMANCLUB is a men’s suicide prevention charity, offering free-to-attend peer-to-peer support groups across the UK and online. The organisation was founded in 2016, to end the stigma surrounding men’s mental health and help men through the power of conversation. The organisation is close to our hearts at Invenia Group, so our team chose to participate in Movember to raise money for this well-deserving charity. You can help us by donating here: https://lnkd.in/e7aJebhm To find out more about Andy's Man Club, take a look at their website, here: https://lnkd.in/dZk9TKA #ITSOKAYTOTALK

#Lifescience #startups , are you hiring for experience or cultural fit? Finding the right balance between both aspects can be a difficult task. In this blog, we walk you through the importance of balancing the two, and how to do so successfully: https://lnkd.in/e97bXtpg

🤖 𝗦𝗵𝗮𝗽𝗶𝗻𝗴 𝘁𝗵𝗲 𝗙𝘂𝘁𝘂𝗿𝗲 𝗼𝗳 𝗥𝗼𝗯𝗼𝘁𝗶𝗰 𝗦𝘂𝗿𝗴𝗲𝗿𝘆: 🤖 𝗞𝗲𝘆 𝗗𝗿𝗶𝘃𝗲𝗿𝘀 𝗮𝗻𝗱 𝗖𝗵𝗮𝗹𝗹𝗲𝗻𝗴𝗲𝘀 𝗶𝗻 𝘁𝗵𝗲 𝗦𝘂𝗿𝗴𝗶𝗰𝗮𝗹 𝗥𝗼𝗯𝗼𝘁𝗶𝗰𝘀 𝗦𝗽𝗮𝗰𝗲... 💭 What’s fueling surgical robotics, and what barriers stand in the way? 💭 If you’re interested in the 𝗛𝗢𝗧𝗧𝗘𝗦𝗧 𝗧𝗢𝗣𝗜𝗖 𝗜𝗡 𝗠𝗘𝗗𝗧𝗘𝗖𝗛... 𝗦𝗨𝗥𝗚𝗜𝗖𝗔𝗟 𝗥𝗢𝗕𝗢𝗧𝗜𝗖𝗦, then this one's for you. I recently authored and published an article on Surgical Robotics Technology website. In this piece, I dive into the critical growth factors and the top challenges impacting surgical robotics. 𝗛𝗲𝗿𝗲 𝗮𝗿𝗲 3️⃣ 𝗺𝗮𝗷𝗼𝗿 𝗽𝗼𝗶𝗻𝘁𝘀 𝗜 𝗰𝗼𝘃𝗲𝗿: 🔬 How rapid technological advancements and #innovation are driving precision and efficacy in #surgical procedures.... 📈 What the current market dynamics for #surgicalrobotic systems mean for developers and investors alike... 📓 The implications of complex, changing, economic and regulatory landscapes on development timelines and market entry.... A huge thank you to the following for their collaboration, their insights and their wisdom into this piece: 🤖 Greg Roche , CEO Distalmotion 🤖 Jaume Amat Riera , CEO Rob Surgical 🤖 Jerry Chen , CEO Brain Navi Biotechnology Co., Ltd. 𝗖𝗵𝗲𝗰𝗸 𝗼𝘂𝘁 𝘁𝗵𝗲 𝗳𝘂𝗹𝗹 𝗮𝗿𝘁𝗶𝗰𝗹𝗲 𝘁𝗼 𝗲𝘅𝗽𝗹𝗼𝗿𝗲 𝗵𝗼𝘄 𝘁𝗵𝗲𝘀𝗲 𝗱𝘆𝗻𝗮𝗺𝗶𝗰𝘀 𝗰𝗼𝘂𝗹𝗱 𝘀𝗵𝗮𝗽𝗲 𝘁𝗵𝗲 𝘀𝘂𝗿𝗴𝗶𝗰𝗮𝗹 𝗿𝗼𝗯𝗼𝘁𝗶𝗰𝘀 𝘀𝗽𝗮𝗰𝗲 𝗶𝗻 𝟮𝟬𝟮𝟱 𝗮𝗻𝗱 𝗯𝗲𝘆𝗼𝗻𝗱: ⤵ https://lnkd.in/ebtxgFpD As always, I’d love to hear your thoughts! How do you think these trends will impact the #Medtech landscape? #medtech #medicaldevice #surgicalrobotics #roboticsurgery #robotics #roboticassistedsurgery #minimallyinvasivesurgery #mis #surgical #executivesearch #executiverecruitment #healthtech #healthcare #innovation Surgical Robotics Technology Josef de Pfeiffer

Tanya Ridding

We're #hiring a new Head of Plant in Taiwan. Apply today or share this post with your network.

🗞️𝐎𝐜𝐭𝐨𝐛𝐞𝐫 𝐁𝐢𝐨𝐭𝐞𝐜𝐡 𝐍𝐞𝐰𝐬🗞️ 𝗧𝗵𝗶𝘀 𝗿𝗼𝘂𝗻𝗱-𝘂𝗽 𝗶𝗻𝗰𝗹𝘂𝗱𝗲𝘀: 🏢𝗔𝗰𝗾𝘂𝗶𝘀𝗶𝘁𝗶𝗼𝗻𝘀, 𝐒𝐩𝐢𝐧 𝐎𝐮𝐭𝐬 𝗮𝗻𝗱 𝗘𝘅𝗽𝗮𝗻𝘀𝗶𝗼𝗻𝘀 from: Vizgen , Ultima Genomics , Eurofins , SYNLAB International , LabGenomics USA , IMD™ , Trinity Biotech , EpiCapture Limited , Bruker , Dynamic Biosensors | a Bruker company , Twist Bioscience , XOMA Royalty , Curiox Biosystems , SPT Labtech and ICE Bioscience ⚖️𝗟𝗲𝗴𝗮𝗹 𝘂𝗽𝗱𝗮𝘁𝗲𝘀 from: Bruker and CareDx, Inc. etc. 🤝𝟯𝟲 𝗰𝗼𝗹𝗹𝗮𝗯𝗼𝗿𝗮𝘁𝗶𝗼𝗻𝘀 𝗮𝗻𝗱 𝗽𝗮𝗿𝘁𝗻𝗲𝗿𝘀𝗵𝗶𝗽 𝗮𝗻𝗻𝗼𝘂𝗻𝗰𝗲𝗺𝗲𝗻𝘁𝘀 including: Akoya Biosciences, Inc. , Fulgent Genetics , MGI , OncoDNA , Dovetail Genomics , CareDx, Inc. , Avacta Therapeutics , Tempus AI , Pillar Biosciences Incorporated , Illumina , 10x Genomics , Velsera , Diagnostica Longwood , Codexis, Inc. , Alphazyme LLC , Owkin , AstraZeneca , 🔬𝗢𝘃𝗲𝗿 𝟰𝟬 𝗽𝗿𝗼𝗱𝘂𝗰𝘁 𝘂𝗽𝗱𝗮𝘁𝗲𝘀 including: Universal Sequencing Technology , Ionpath , CD Genomics , SeqOne , PacBio , Creative Proteomics , Parse Biosciences etc. #biotech #biotechnews #lifesciences #genomics #partnerships #proteomics #bioinformatics #cellbiology #diagnostics

Katie Davis

An industry global leader required a Director of #Scientific Affairs, East Coast US. This would be a brand-new function, requiring the individual to amplify brand awareness and develop relationships with industry leaders. Our approach involved closely managing timelines and adapting our search based on the company’s evolving needs. Given the novelty of the position, we brought a variety of profiles to the table, refining our search criteria through iterative feedback from the company’s board. Read the full case study here: https://lnkd.in/eiWSScT8

Big news out of the HC Data space: 23andMe has announced it will be shutting down its therapeutics development division. The company is now on the look out for buyers in order to rehome its in-house pipeline of DNA-informed immuno-oncology antibody drugs. The major focus of 23andMe will now be placed on the personalized DNA and ancestry tests that first helped launch the company into the limelight. They will also continue to provide their telehealth platforms and research services to other drugmakers in the space. If the proposed acquisition does take place it raises many questions not only for consumers but also for those in the pharma, and regulatory spaces. What goes into acquiring such large, global datasets? What safeguarding measure must be implemented to ensure correct handling and use of the data once aquired? Above all else it raises the question, how can this already gathered data be used? Will the buyers adhere to solely using the data in ways authorized by the huge consumer base that have submitted their DNA? With these changes the company has stated it will layoff up to 40% of its staff as it continues to repivot and change focus. My team and I at Invenia Group are currently working extensively across the Genetics, Drug Development, and Healthcare Data space throughout the UK, Europe, and North America. Any 23andMe employees who have been impacted by recent and upcoming changes, please feel free to reach out to discuss next steps and new opportunities. Invenia Group Katie Davis Andrew Maddison #hiring #layoffs #23andme #genomics #genetics #RWD #RWE

Marc O.

New #vacancies this week! We have partnered with an incredible range of fast-growing and leading #lifescience , #medtech & #biopharma companies across Europe and the US. To find out more information, head over to our jobs page here: https://rb.gy/19iaq7 Director of Regulatory Affairs - Maryland, US: https://lnkd.in/e4AsSZGz Inside Sales Specialist - US: https://lnkd.in/ee3-nedD Inside Sales Account Manager - France: https://lnkd.in/e5zn4XEq Field Application Specialist - Belgium: https://lnkd.in/ePWB74Ui Business Development Manager - Netherlands: https://lnkd.in/eCEJ-W_D Program Management Office Coordinator - Netherlands: https://lnkd.in/eFUBn8NZ Haven't seen anything that's right for you? Why not register with us instead so we can find you your perfect role: https://lnkd.in/dpZiviy Ready to talk to a specialist recruiter to discuss a vacancy or set of vacancies? Maybe you’d like to learn more about our recruitment services? Get in touch here: https://lnkd.in/e9D6pugm

It's always great to see the growing ventures coming out of the #Cambridge Life Science scene. Start-up and scale up companies in Cambridge alone raised over $1.3B in the last 12 months, and have garnered interest from leading investors on a global scale. With the help of international backers these companies will continue to be at the forefront of driving development across Drug Discovery & Development, HC Data Analytics, and Precision Medicine. It's exciting to work so closely with the innovative companies coming out of Cambridge, and I look forward to seeing the growth continue into 2025. A handful of rounds closed in 2024 include: Zetta Genomics Ltd CEO: Ignacio Medina $2.35 (£1.8m) Seed Round – February 2024 Investors: We Venture Capital , Nina Capital , APEX Ventures , University of Cambridge Enterprise Sano Genetics CEO: Patrick Short $11.4m (£9m) Series A – January 2024 Investors: MMC Ventures , Episode 1 Ventures , Seedcamp Biofidelity CEO: Barney Balmforth $24m Venture Round – April 2024 Investors: Agilent Technologies , BlueYard Capital , Longwall Venture Partners LLP Ventures, Octopus Ventures clock.bio CEO: Markus Gstöttner $5.3m Seed Round – October 2024 Investors: LocalGlobe , BlueYard Capital Psyomics CEO: Melinda Rees $5.2m (£4m) Venture Round – June 2024 Investors: Parkwalk Advisors Invenia Group #digitalhealth #cambridge #genomics #healthcare

We're #hiring a new Program Management Office Coordinator in South Holland. Apply today or share this post with your network.

Metric
Company Name	Invenia Group
Symbol
MSH ID	COM:INVENIAGROUP
Market	PRIVATE
Sector	Commercial & Professional Services
Industry	Recruitment & Staffing
Country	US
Stage
Employee Count
Website	inveniagroup.com
LinkedIn	invenia-group-ltd
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

INVE

COM:INVENIAGROUP

Invenia Group

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue